The Clatterbridge Cancer Centre
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 4th November 2021

[redacted]

Re: Freedom of Information Request Ref: 299-2021

Thank you for your email dated the 8th October 2021, requesting information in relation to treatment of cancer.

The information that you require is as follows:

Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000.The areas where this exemption has been applied are shown below:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- **Afatinib = 0**
- **Alectinib = 0**
- **Atezolizumab monotherapy = 0**
- **Atezolizumab with chemotherapy = 0**
- **Bevacizumab = 0**
- **Brigatinib = 0**

- **Ceritinib = 0**
- **Crizotinib = Exempt under S.40**
- **Dacomitinib = Exempt under S.40**
- **Dabrafenib with Trametinib =0**
- **Docetaxel monotherapy or combination with Carboplatin/Cisplatin = Exempt under S.40**
- **Durvalumab = 14**
- **Erlotinib = 11**
- **Gefitinib = Exempt under S.40**
- **Gemcitabine = 0**
- **Lorlatinib = Exempt under S.40**
- **Nintedanib with Docetaxel = 7**
- **Nivolumab = Exempt under S.40**
- **Osimertinib = 49**
- **Paclitaxel = 0**
- **Pembrolizumab monotherapy = 129**
- **Pembrolizumab with chemotherapy = 17**
- **Pemetrexed with Carboplatin/Cisplatin = 71**
- **Vinorelbine with Carboplatin/Cisplatin = 43**
- **Any other active systemic anti-cancer therapy (SACT) = 75**
- **Palliative care only = This data is not recorded**

Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

- **Atezolizumab monotherapy = 8**
- **Atezolizumab with chemotherapy = 0**
- **Durvalumab = Exempt under S.40**
- **Gemcitabine = 0**
- **Nivolumab = Exempt under S.40**
- **Osimertinib = 0**
- **Paclitaxel = 0**
- **Pembrolizumab (Keytruda) Mono = 40**
- **Pembrolizumab (Keytruda) with Chemotherapy = 12**
- **Other active systemic anti-cancer therapy (SACT) = Exempt under S.40**
- **Palliative care only = This data is not recorded**

Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

Non-Small Cell Lung Cancer – Open to Recruitment

Project Short Title	Project Full title	Project type	Recruited
National Lung Matrix	National Lung Matrix Trial: Multi--drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	Non-commercial portfolio	7
SARON	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial.	Non-commercial portfolio	16
HALT	Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	Non-commercial portfolio	Exempt under S.40
ACZ885 CANAKINUMAB (CANOPY)	A phase III, multicenter, randomised, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	Commercial portfolio	Exempt under S.40
KEYNOTE 671	A Phase III, Randomised, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Commercial portfolio	Exempt under S.40
IMPower	A Phase III, Double-Blinded, Multicenter, Randomised Study Evaluating The Efficacy And Safety Of Neoadjuvant Treatment With Atezolizumab Or Placebo In Combination With Platinum-Based Chemotherapy In Patients With Resectable Stage Ii, Iiia, Or Select Iiib Non−Small Cell Lung Cancer	Commercial portfolio	Exempt under S.40
KEYNOTE 867	A Phase 3, Randomised, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)	Commercial portfolio	0

CA209-73L	A Phase 3, Randomised, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)	Commercial portfolio	Exempt under S.40
FLAURA-2	A phase III, open-label, randomised study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2)	Commercial portfolio	Exempt under S.40

Non-Small Cell Lung Cancer – Follow-up

Project Short Title	Project Full title	Project type	Recruited
CHECKMATE 171	Checkmate 171: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC	Commercial portfolio	23
LDK378 Food Affect Study	A Phase I, multi-center, randomised open label study to assess the systemic exposure and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)	Commercial portfolio	7
ABI-007-NSCL-006	A Phase 2, randomised, open-label, multicenter study to assess safety and efficacy of nabpaclitaxel (Abraxane) with epigenetic modifying therapy of CC-486, and nab-paclitaxel monotherapy as second-line treatment in subjects with advanced nonsquamous non-small cell	Commercial portfolio	16

	lung cancer (NSCLC): ABOUND.2L		
ADSCAN	A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer.	Non-commercial portfolio	Exempt under S.40
XALT-3	Phase 3 Randomised Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients	Commercial portfolio	Exempt under S.40
CHECKMATE 817	Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies	Commercial portfolio	6
PS2	A Phase III, open-label, multicentre, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.	Commercial portfolio	Exempt under S.40
LEAP-006	A Phase 3 Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	Commercial portfolio	Exempt under S.40
LUNG ART	Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement	Non-commercial portfolio	Exempt under S.40
IDEAL-CRT	Isotoxic Dose Escalation and Acceleration in Lung Cancer ChemoRadiotherapy - A phase I/II trial of concurrent chemoradiation with dose-escalted radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer	Non-commercial portfolio	10

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.
Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY.

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

https://www.surveymonkey.co.uk/r/H39RFMM

Kind regards

Margaret Moore
Information Governance Administrator
Contact Email: ccf-tr.foi@nhs.net